Literature DB >> 8095924

T-cell-dependent and T-cell-independent mechanisms of tolerance to glucuronoxylomannan of Cryptococcus neoformans serotype A.

J B Sundstrom1, R Cherniak.   

Abstract

Glucuronoxylomannan (GXM), a type 2 T-independent antigen, is the major component of the capsular polysaccharide (CnCAP) of Cryptococcus neoformans. Previous studies have described the tolerogenic effects of high doses of CnCAP on the specific humoral response. In this investigation, evidence for both high-dose and low-dose tolerance to GXM is presented. BALB/cBy female mice, primed with either 5 ng or 50 micrograms of GXM, then coimmunized 3 days later with immunogenic doses of both GXM and type 3 pneumococcal polysaccharide (SSS-III), showed an antigen-specific inhibition in their splenic plaque-forming cell (PFC) responses to GXM compared with control groups primed with normal saline. SSS-III PFCs remained unchanged between GXM-primed and normal saline-primed groups. Low-dose tolerance appeared to be T dependent, whereas high-dose tolerance appeared to be T independent. Low-dose tolerance to GXM could not be induced in athymic BALB/c nu/nu mice, whereas high-dose tolerance in the same mice could be induced. Furthermore, low-dose tolerance was adoptively transferred with B-cell-depleted splenocytes to naive BALB/c mice, while high-dose tolerance was not. Complement-mediated depletion of CD4+ but not CD8+ splenocytes from low-dose-primed mice abrogated the transfer of low-dose tolerance. These findings indicate T-dependent and T-independent mechanisms of antigen-specific B-cell tolerance to GXM in BALB/c mice at low and high antigen doses, respectively.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8095924      PMCID: PMC281368          DOI: 10.1128/iai.61.4.1340-1345.1993

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  27 in total

1.  Tolerance induction in resting memory B cells specific for a protein antigen.

Authors:  J G Johnson; R Jemmerson
Journal:  J Immunol       Date:  1992-05-01       Impact factor: 5.422

2.  Lymphokine control of type 2 antigen response. IL-10 inhibits IL-5- but not IL-2-induced Ig secretion by T cell-independent antigens.

Authors:  L M Peçanha; C M Snapper; A Lees; J J Mond
Journal:  J Immunol       Date:  1992-06-01       Impact factor: 5.422

Review 3.  TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties.

Authors:  T R Mosmann; R L Coffman
Journal:  Annu Rev Immunol       Date:  1989       Impact factor: 28.527

4.  In vivo kinetics and characterization of IFN-gamma-producing cells during a thymus-independent immune response.

Authors:  A J van den Eertwegh; M J Fasbender; M M Schellekens; A van Oudenaren; W J Boersma; E Claassen
Journal:  J Immunol       Date:  1991-07-15       Impact factor: 5.422

5.  Induction of self-tolerance in T cells but not B cells of transgenic mice expressing little self antigen.

Authors:  S Adelstein; H Pritchard-Briscoe; T A Anderson; J Crosbie; G Gammon; R H Loblay; A Basten; C C Goodnow
Journal:  Science       Date:  1991-03-08       Impact factor: 47.728

6.  Inactivation of suppressor T-cell activity by nontoxic monophosphoryl lipid A.

Authors:  P J Baker; J R Hiernaux; M B Fauntleroy; B Prescott; J L Cantrell; J A Rudbach
Journal:  Infect Immun       Date:  1988-05       Impact factor: 3.441

7.  Galactoxylomannans of Cryptococcus neoformans.

Authors:  P G James; R Cherniak
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

8.  Glucuronoxylomannan of Cryptococcus neoformans serotype B: structural analysis by gas-liquid chromatography-mass spectrometry and 13C-nuclear magnetic resonance spectroscopy.

Authors:  S H Turner; R Cherniak
Journal:  Carbohydr Res       Date:  1991-04-02       Impact factor: 2.104

9.  Facilitated isolation, purification, and analysis of glucuronoxylomannan of Cryptococcus neoformans.

Authors:  R Cherniak; L C Morris; B C Anderson; S A Meyer
Journal:  Infect Immun       Date:  1991-01       Impact factor: 3.441

10.  Immunosuppression in experimental cryptococcosis in rats. Induction of efferent T suppressor cells to a non-related antigen.

Authors:  D T Masih; C E Sotomayor; H R Rubinstein; C M Riera
Journal:  Mycopathologia       Date:  1991-06       Impact factor: 2.574

View more
  9 in total

Review 1.  Virulence factors of medically important fungi.

Authors:  L H Hogan; B S Klein; S M Levitz
Journal:  Clin Microbiol Rev       Date:  1996-10       Impact factor: 26.132

2.  Immunosuppression, interleukin-10 synthesis and apoptosis are induced in rats inoculated with Cryptococcus neoformans glucuronoxylomannan.

Authors:  Laura S Chiapello; José L Baronetti; María P Aoki; Susana Gea; Héctor Rubinstein; Diana T Masih
Journal:  Immunology       Date:  2004-11       Impact factor: 7.397

3.  Immunoglobulin G monoclonal antibodies to Cryptococcus neoformans protect mice deficient in complement component C3.

Authors:  Scott Shapiro; David O Beenhouwer; Marta Feldmesser; Carlos Taborda; Michael C Carroll; Arturo Casadevall; Matthew D Scharff
Journal:  Infect Immun       Date:  2002-05       Impact factor: 3.441

Review 4.  Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans.

Authors:  T G Mitchell; J R Perfect
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

5.  Molecular structures that influence the immunomodulatory properties of the lipid A and inner core region oligosaccharides of bacterial lipopolysaccharides.

Authors:  P J Baker; T Hraba; C E Taylor; P W Stashak; M B Fauntleroy; U Zähringer; K Takayama; T R Sievert; X Hronowski; R J Cotter
Journal:  Infect Immun       Date:  1994-06       Impact factor: 3.441

6.  Tissue localization of Cryptococcus neoformans glucuronoxylomannan in the presence and absence of specific antibody.

Authors:  D L Goldman; S C Lee; A Casadevall
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

Review 7.  Polysaccharide antigens of the capsule of Cryptococcus neoformans.

Authors:  R Cherniak; J B Sundstrom
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

8.  Variation in the structure of glucuronoxylomannan in isolates from patients with recurrent cryptococcal meningitis.

Authors:  R Cherniak; L C Morris; T Belay; E D Spitzer; A Casadevall
Journal:  Infect Immun       Date:  1995-05       Impact factor: 3.441

9.  Antibodies to the Cryptococcus neoformans capsular glucuronoxylomannan are ubiquitous in serum from HIV+ and HIV- individuals.

Authors:  M Deshaw; L A Pirofski
Journal:  Clin Exp Immunol       Date:  1995-03       Impact factor: 4.330

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.